<DOC>
	<DOCNO>NCT00670449</DOCNO>
	<brief_summary>This study extension study NCT00537082 . This study design evaluate efficacy safety long-term administration 0.5 mg 1.25 mg fingolimod ( FTY720 ) relapse multiple sclerosis .</brief_summary>
	<brief_title>An Extension Study Efficacy Safety Fingolimod ( FTY720 ) Patients With Relapsing Multiple Sclerosis</brief_title>
	<detailed_description>A decision make switch patient fingolimod 1.25 mg/day fingolimod 0.5 mg/day amendment study protocol . The study become open-label patient receive fingolimod 0.5 mg/day 22 Feb 2010 . The efficacy data Months 0-6 study report core study NCT00537082 .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Patients complete 6 month treatment study drug Month 6 visit core study NCT00537082 . Females childbearing potential negative pregnancy test core study NCT00537082 . Patients permanently discontinue study drug treatment prior Month 6 visit core study NCT00537082 . Other protocoldefined inclusion/exclusion criterion apply study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>FTY720</keyword>
	<keyword>multiple sclerosis</keyword>
	<keyword>MS</keyword>
</DOC>